WNT9B and neoplasm: For PFS cytoplasmatic WNT9B was found to be associated with better patient survival in the tumour cells (p = 0.029) as well as in the stroma (p = 0.017), which was confirmed (HR 0.67, 95% CI 0.48–0.92, p = 0.014) by multivariate analysis for the expression in the TME (Supplementary Fig. 8a–k and Supplementary Table 11).